
Schizophrenia
In this topic library devoted to schizophrenia you’ll find helpful resources for diagnosis and treatment—best-practice guidelines, decision-support tools, and research summaries. Each week, new content publishes, so check back often to stay up to date.

Featured Resources

Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target for the Treatment of Schizophrenia
-
Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
InfographicAugust 31, 2023 -
Hot Topics: Clinical Questions in Schizophrenia – Question II
InterviewMarch 15, 2023Dr. Christoph U. Correll will address current and relevant clinical questions relating to schizophrenia. These questions and Dr. Correll’s response… -
Linking Neural Circuits To Dysfunction In Schizophrenia
On-Demand WebinarApril 6, 2023We have known dysfunction in certain neural circuit pathways ultimately led to symptoms in schizophrenia. These aberrant pathways caused downstream…

Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
-
1.8% Of U.S. Adults Have Schizophrenia Spectrum Disorders
ArticleJuly 17, 2023 -
Obesity Increases Risk Of Mental Disorders Throughout Life
ArticleJuly 10, 2023 -
The Curious Case Of Metabolic Dysfunction In Schizophrenia: Who’s Susceptible & Why?
On-Demand WebinarJune 22, 2023
Advisors
-
Christoph Correll, MD
Schizophrenia Section Advisor
Ask A Question About Schizophrenia
Enter your question in the box below and click “Ask My Question” to submit your inquiry.
You must be logged in to ask a question in this section.
Disclaimer: The information provided by PsychU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Treatment-related questions will not be addressed. Users seeking medical advice should consult with their physician or other healthcare professional.
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) operates in a highly regulated and scrutinized industry. Therefore, we may not be able to address every questions or topic submitted. Topics which may not be addressed may include, but are not limited to questions related to: (1) specific medications, (2) branded items, (3) clinical or treatment advice relating to specific patient conditions. The lack of response to certain questions or comments should not be taken as an agreement with the view posed or an admission of any kind.
REQUEST A PRESENTATION
Request a free educational program for your organization or region today! These customizable PsychU presentations are available both online and in-person, and cover a range of topics including: schizophrenia, major depressive disorder, bipolar disorder, care coordination, quality standards, and more.
Top Requested Presentations
Agitation Associated With Alzheimer’s Dementia Disease State Education
The Importance Of Population Health: A Mental Health Perspective